Multiple Wall Street analysts, including Morgan Stanley and Goldman Sachs, updated their research on Legend Biotech. While maintaining their ratings, most adjusted their price targets downward, indicating a revised valuation perspective for the company.
On November 12, 2026, several prominent Wall Street firms, including Morgan Stanley, Goldman Sachs, Barclays, and Oppenheimer, revised their price targets for Legend Biotech downwards, while maintaining their existing ratings. H.C. Wainwright was an outlier, maintaining both its rating and price target. This collective downward adjustment in price targets suggests a re-evaluation of Legend Biotech's near-term growth prospects or market valuation by a significant portion of the analyst community. For traders, this could signal potential short-term downward pressure on the stock as the market digests these revised valuations, though the maintained ratings suggest underlying confidence in the company's long-term fundamentals. The key risk is further analyst downgrades or continued price target reductions if new negative information emerges.